Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Shares Outstanding (Diluted Average) (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Shares Outstanding (Diluted Average) for 9 consecutive years, with $16.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 87.98% to $16.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $16.8 million, a 87.98% increase, with the full-year FY2024 number at $9.0 million, up 1.94% from a year prior.
  • Shares Outstanding (Diluted Average) was $16.8 million for Q3 2025 at Marker Therapeutics, up from $12.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $83.1 million in Q3 2021 to a low of $7.7 million in Q4 2021.
  • A 5-year average of $19.7 million and a median of $8.9 million in 2024 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): crashed 89.96% in 2022, then soared 87.98% in 2025.
  • Marker Therapeutics' Shares Outstanding (Diluted Average) stood at $7.7 million in 2021, then rose by 9.16% to $8.4 million in 2022, then grew by 5.49% to $8.8 million in 2023, then rose by 1.94% to $9.0 million in 2024, then skyrocketed by 86.61% to $16.8 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Shares Outstanding (Diluted Average) are $16.8 million (Q3 2025), $12.5 million (Q2 2025), and $11.1 million (Q1 2025).